~~<i id='13D6D21352'><strike id='13D6D21352'><tt id='13D6D21352'><pre id='13D6D21352'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：knowledge 2025-09-29 06:21:21 Page View：81316

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC
Next article： Drug repurposing or repositioning? The language matters

comprehensive

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Biden warns of ‘dark winter’ during final presidental debate

DemocraticpresidentialcandidateformerVicePresidentJoeBidenanswersaquestionasPresidentTrumplistensdur

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

What we know about the American soldier detained in North Korea

1:03SouthKoreanarmysoldierspassbyamilitaryguardpostattheImjingakPavilioninPaju,SouthKorea,nearthebor